跳至主要内容
临床试验/RBR-8fdnky
RBR-8fdnky招募中未知

Bulk fill composite resins: randomized and double-blind clinical trial

Departamento de Odontologia Restauradora da Universidade Federal do Ceará0 个研究点开始时间: 2018年5月9日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Intervention

入排标准

年龄范围
18Y 至 60Y(—)

入选标准

  • All included patients will require at least five class I or II restorations in molars or premolars. The causes for composite resin restorations in this study may be fractures, large misalignments or other defects in existing amalgam restorations, or replacement of amalgam restorations for aesthetic reasons. In that case, the request must be made by the patient. Patients must be at least 18 years. Patients should have good general health, acceptable oral hygiene and availability of return during the evaluation periods. All teeth included in the study should have a normal occlusal relationship with the natural antagonist tooth, at least one contact with the adjacent tooth and those with marked occlusal stress, evidenced by severe occlusal wear, will be excluded. The cavities may involve enamel and dentin and should have a minimum depth of 3 mm.

排除标准

  • Pregnancy or breastfeeding, non-vital tooth, allergies and idiosyncratic responses to product ingredients, occlusal contactless tooth with or without proximal contact, orthodontic treatment for less than 3 months, history of existing tooth sensitivity, prosthetic teeth fixed or removable, periodontal surgery performed less than 3 months ago, teeth or supporting structures with any painful pathology, bruxism, periodontal disease, known allergy to resinous materials, cavities to be restored shallow and / or narrow, impossibility to return to the recalls , fractured or visibly cracked teeth.

研究者

发起方
Departamento de Odontologia Restauradora da Universidade Federal do Ceará

相似试验

尚未招募
不适用
Comparison of the efficacy of dexmedetomidine and fentanyl on emergence agitation.
CTRI/2019/06/019709Sri Ramachandra Medical university
进行中(未招募)
不适用
A PHASE 2 DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE SAFETY, TOLERABILITY AND PHARMACOKINETICS/ PHARMACODYNAMICS OF PF-04360365 IN MILD TO MODERATE ALZHEIMER’S DISEASE PATIENTSMild to Moderate Alzheimer's DiseaseMedDRA version: 9.1Level: LLTClassification code 10001896Term: Alzheimer's disease
EUCTR2009-011172-30-SEPfizer Inc, 235 East 42nd Street, New York, NY 1001736
进行中(未招募)
不适用
A PHASE 2A RANDOMIZED DOUBLE-BLINDED, PLACEBO AND ACTIVE CONTROLLED TWO COHORT TWO DOSES CROSS-OVER MULTI-CENTER CLINICAL STUDY TO ASSESS EFFICACY OF A ONCE DAILY ADMINISTRATION OF A PHOSPHODIESTERASE 5 INHIBITOR (PF-00489791) FOR THE TREATMENT OF VASOSPASM IN PRIMARY AND SECONDARY RAYNAUD’S PHENOMENO
EUCTR2010-019009-40-CZPfizer Ltd, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK208
进行中(未招募)
不适用
A PHASE 2A RANDOMIZED DOUBLE-BLINDED, PLACEBO AND ACTIVE CONTROLLED TWO COHORT TWO DOSES CROSS-OVER MULTI-CENTER CLINICAL STUDY TO ASSESS EFFICACY OF A ONCE DAILY ADMINISTRATION OF A PHOSPHODIESTERASE 5 INHIBITOR (PF-00489791) FOR THE TREATMENT OF VASOSPASM IN PRIMARY AND SECONDARY RAYNAUD’S PHENOMENOTreatment of Vasospasm in Primary and Secondary Raynaud’s PhenomenonMedDRA version: 12.1Level: LLTClassification code 10037912Term: Raynaud's phenomenon
EUCTR2010-019009-40-SEPfizer Ltd, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK208
进行中(未招募)
不适用
A PHASE 2A RANDOMIZED DOUBLE-BLINDED, PLACEBO AND ACTIVE CONTROLLED TWO COHORT TWO DOSES CROSS-OVER MULTI-CENTER CLINICAL STUDY TO ASSESS EFFICACY OF A ONCE DAILY ADMINISTRATION OF A PHOSPHODIESTERASE 5 INHIBITOR (PF-00489791) FOR THE TREATMENT OF VASOSPASM IN PRIMARY AND SECONDARY RAYNAUD’S PHENOMENOTreatment of Vasospasm in Primary and Secondary Raynaud’s PhenomenonMedDRA version: 12.1Level: LLTClassification code 10037912Term: Raynaud's phenomenon
EUCTR2010-019009-40-HUPfizer Ltd, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK208